Hyperbaric Oxygen in Critical Care

Published on 22/03/2015 by admin

Filed under Critical Care Medicine

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1660 times

56 Hyperbaric Oxygen in Critical Care

Hyperbaric oxygen (HBO2) treatment involves intermittent breathing of pure oxygen at greater than ambient pressure. Over the past 20 years, HBO2 has undergone refinement, with increased understanding of mechanisms of action and clinical applications. Along with an expansion of the knowledge base, formalized education now exists for emergency, critical care/anesthesia, and surgically trained physicians, who may obtain special competency board certification through the American Board of Medical Specialists. This chapter will summarize existing literature on uses for hyperbaric oxygen therapy and some special issues related to care of critically ill patients.

image Applications

HBO2 treatment is carried out in either a monoplace (single person) or multiplace (typically 2 to 14 patients) chamber. Pressures applied while in the chamber are usually 2 to 3 atmospheres absolute (ATA), representing the sum of the atmospheric pressure plus additional hydrostatic pressure equivalent to 1 or 2 atmospheres. Treatments usually are for 2 to 8 hours, depending on the indication, and may be performed from 1 to 3 times daily. Monoplace chambers are usually compressed with pure oxygen. Multiplace chambers are pressurized with air, and patients breathe pure oxygen through a tight-fitting facemask, hood, or endotracheal tube. During treatment, the PaO2 typically exceeds 2000 mm Hg, and levels of 200 to 400 mm Hg occur in tissues.1

HBO2 should be viewed as a drug and the hyperbaric chamber as a dosing device. Elevating tissue oxygen tension is a primary effect. Although this may alleviate physiologic stress to hypoxic tissues, lasting benefits of HBO2 must relate to abatement of underlying pathophysiologic processes. The accepted indications comprise a heterogeneous group of disorders (Box 56-1), thus implying that there are several mechanisms of action for HBO2 (Box 56-2).13

Arterial Gas Embolism and Decompression Sickness

Among the earliest application of hyperbaric therapy was to treat disorders related to gas bubbles in the body. Compressed air construction work required exposure to elevated ambient pressure within compartments (caissons) for many hours to excavate tunnels or bridge foundations in muddy soil that otherwise would flood. In the 19th century, workers were noted to frequently experience joint pains, limb paralysis, or pulmonary compromise when they returned to ambient pressure. This condition—decompression sickness (DCS), caisson disease, or bends—was later attributed to nitrogen bubbles in the body, and recompression was found to relieve symptoms. The mechanism, based purely on Boyle’s law, with reduction of gas bubble volume due to pressure, was later improved by adding supplemental oxygen to hasten inert gas diffusion out of the body. Similar observations were made at later times for scuba divers, who are also prone to develop arterial gas embolism (AGE) due to pulmonary overpressurization on decompression.

Iatrogenic AGE has been reported in association with cardiovascular, obstetric/gynecologic, neurosurgical, and orthopedic procedures and generally whenever disruption of a vascular wall occurs. Nonsurgical processes reported to cause AGE include overexpansion during mechanical ventilation, hemodialysis, and after accidental opening of central venous catheters.4

Treatment of gas bubble disorders includes standard support of airway, breathing, and circulation plus prompt application of HBO2. Gas bubbles have been reported to persist for several days, and although delays should be avoided, HBO2 may be beneficial even when begun after long delays.59 Controlled animal trials support efficacy of HBO2, but randomized clinical trials have not been done.10 In their review of 27 case series, Moon and Gorman described substantial benefit with HBO2 treatment—78% of 441 cases receiving HBO2 fully recovered and 4.5 % died, whereas only 26% of 74 cases not undergoing HBO2 treatment fully recovered and 52% died.4

Mechanisms of action of HBO2 in AGE and DCS treatment include reduction of gas according to Boyle’s law, hyperoxygenation to hasten inert gas diffusion, and an additional effect related to inhibition of leukocyte adherence to injured endothelium. Endothelial dysfunction occurs in association with mechanical interactions of bubbles at vessel walls and lumen occlusion.1115 Neutrophil activation and perivascular adherence occur and are associated with functional deficits post decompression.16,4,17 Animals depleted of leukocytes before experimental cerebral air embolism suffer less severe reduction of cerebral blood flow and better neurologic outcome.18 HBO2 has been shown to temporarily inhibit human β2-integrin adhesion function.19 Inhibition of neutrophil β2-integrin adhesion by HBO2 has been described in a number of animal models including skeletal muscle ischemia-reperfusion, cerebral ischemia-reperfusion, pulmonary smoke inhalation injury, and brain injury after carbon monoxide (CO) poisoning.2023 The mechanism for this effect involves S-nitrosylation of cytoskeletal β-actin, which impedes the coordinated cell-surface β2-integrin migration required for firm adherence.24

Carbon Monoxide Poisoning

Carbon monoxide is the leading cause of injury and death by poisoning in the world.25 The affinity of CO for hemoglobin, to form carboxyhemoglobin (COHb), is more than 200-fold greater than that of O2. CO-mediated hypoxic stress is a primary insult, but COHb values correlate poorly with clinical outcome.* Pathologic mechanisms, in addition to elevations of COHb, include intravascular platelet-leukocyte aggregation, leukocyte-mediated oxidative injury to brain, excessive release of excitatory amino acids such as glutamate, impaired mitochondrial oxidative phosphorylation, and possible myocardial calcium overload. Survivors of acute CO poisoning are at risk for developing delayed neurologic sequelae (DNS) that include cognitive deficits, memory loss, dementia, parkinsonism, paralysis, chorea, cortical blindness, psychosis, personality changes, and peripheral neuropathy. DNS typically occurs from 2 to 40 days after poisoning, and the incidence is from 25% to 50% after severe poisoning.

References 3339.

Administration of supplemental oxygen is the cornerstone of treatment for CO poisoning. Oxygen inhalation will hasten dissociation of CO from hemoglobin as well as provide enhanced tissue oxygenation. HBO2 causes carboxyhemoglobin dissociation to occur at a rate greater than that achievable by breathing pure oxygen at sea level. Additionally, HBO2, but not ambient pressure oxygen treatment, has several actions that have been demonstrated in animal models to be beneficial in ameliorating pathophysiologic events associated with central nervous system (CNS) injuries mediated by CO. These include an improvement in mitochondrial oxidative processes,40 inhibition of lipid peroxidation,41 and impairment of leukocyte adhesion to injured microvasculature.22 Animals poisoned with CO and treated with HBO2 have been found to have more rapid improvement in cardiovascular status,42 lower mortality,43 and lower incidence of neurologic sequelae.44

Despite online criticisms of their analysis, a meta-analysis by the Cochrane Library concluded that it is unclear whether HBO2 reduces the incidence of adverse CO-mediated neurologic outcomes.45 There are five prospective, randomized trials that have assessed clinical efficacy of HBO2 for acute CO poisoning.30,31,32,46,47 Several failed to find benefit,30,47 but methodological weaknesses discussed by several authors39,48 diminish their clinical impact. Only one clinical trial satisfies all items deemed to be necessary for the highest quality of randomized controlled trials.49 HBO2 treatment also appears to diminish acute mortality, based on a retrospective analysis.48

Blood Loss Anemia

In rare instances when transfusion is not possible due to cross-matching incompatibilities or religious beliefs, intermittent use of HBO2 has been applied to temporarily relieve physiologic stress from severe acute anemia. Anecdotal reports describe using 2.5 to 3.0 ATA O2 to raise PaO2 in plasma to meet metabolic needs.5053 Treatments are often administered for only brief times when physiologic decompensation occurs, because O2 toxicity can be a problem (see later discussion). Short-term treatments, applied many times over several days, have been used to support life until red cells become available or until adequate red cell mass is generated endogenously.

Clostridial Myonecrosis (Gas Gangrene)

Successful treatment of gas gangrene depends on prompt recognition and aggressive intervention. Mortality rates from 11% to 52% have been reported. There are five retrospective comparisons and 13 case series in the literature. These have been discussed in several reviews.1,54,55 Because of difficulties with comparison among patient groups, impartial assessment of HBO2 efficacy based on mortality or “tissue salvage” rates is difficult. Most authors comment on clinical benefits associated with treatment. Temporal improvement of vital signs in patients with gangrene can be among the most dramatic observations in day-to-day practice.

Crush Injury

There is limited experience with HBO2 for acute traumatic peripheral ischemia and suturing of severed limbs. A single randomized controlled trial (involving 36 patients) on this type of injury has been performed, which found HBO2 to improve healing and reduce infection and wound dehiscence.56 In a case series of 23 patients, HBO2 was deemed to improve limb preservation, and it was also observed that the change in transcutaneous tissue oxygen level from ambient to hyperbaric conditions may predict outcome.57 The rationale for considering HBO2 is to temporarily improve oxygenation to hypoperfused tissues and because arterial hyperoxia will cause vasoconstriction that can diminish edema formation.58,59 This latter mechanism has been demonstrated most convincingly in the context of experimental compartment syndrome.60 Broad comparative evaluation of HBO2 treatment for traumatic injuries is described as showing considerable benefit.61

Progressive Necrotizing Infections

The use of HBO2 for treatment of necrotizing fasciitis and Fournier’s gangrene, which are mixed aerobic-anaerobic infections, has been reported in six nonrandomized comparisons and four case series.* As with gas gangrene, variations in time of diagnosis and clinical status on admission compromise assessment of the existing literature. Most studies have reported that when HBO2 is added to surgery and antibiotic therapy, mortality is reduced versus surgery and antibiotics alone. Animal trials have been difficult to assess because synergistic bacterial processes are difficult to establish. One report has found HBO2 to potentiate antibiotics in streptococcal myositis),72 and several animal models of polymicrobial bacteremia and sepsis have reported increased survival with HBO2.7375 Mechanisms of action may include suppressed growth of anaerobic microorganisms and improved bactericidal action of leukocytes (that function poorly in hypoxic conditions).11,7678

Thermal Burns

Some burn centers employ adjunctive HBO2 for severe burns. This is not a universal practice, and controversy persists. Animal models have documented benefits with HBO2 in reducing partial to full-thickness skin loss, hastening epithelialization, and lowering mortality.1 Randomized clinical trials, albeit with small patient numbers, have reported improved rates of healing with shorter hospitalization stays and therefore reduced costs.7982 Uncontrolled series have also reported efficacy, but some studies have failed to find benefit.8385 The rationale for treatment has been based on reducing tissue edema and increasing neovascularization. The latter mechanism has not been directly shown with thermal injuries but is a well-documented effect in applications of HBO2 for wounds.3

image Critical Care in Hyperbaric Medicine

Hyperbaric treatment centers typically have the ability to manage patients who require critical care support. This is accomplished by close cooperation among the treating physicians, nurses, and respiratory therapists and the presence of specialized equipment to manage and monitor the patients.

Plans for treatment begin while the patient is still in the ICU, before transport to the hyperbaric chamber is initiated. Issues to be addressed include informed consent, determination that all intravenous/arterial lines and nasogastric tubes/Foley catheters are secured, capping all unnecessary intravenous catheters, placing chest tubes to one-way Heimlich valves, and adequately sedating or paralyzing the patient as clinically indicated. During transport, emergency drugs for advanced life support resuscitation should be available.

The environment of the hyperbaric chamber imposes limitations on equipment, including space restrictions, fire codes, and the effect of pressure on equipment function. Electrical components of equipment are located outside the hyperbaric chamber. Cables penetrate the chamber bulkhead to make connection to the pneumatic portion of ventilators, internal cardiac pacer wires, electrocardiogram attachments, and arterial line transducers. The patient is attached to equipment at ambient pressure before treatment, and once the treatment pressure is achieved, all settings are checked and transducers recalibrated. It is especially important to remember to check the cuff pressure of endotracheal tubes. Many centers make it a practice to replace the air in these cuffs with an equivalent volume of sterile saline before treatment to avoid volume changes related to pressurization.

There are several intravenous infusion pumps that operate normally in the multiplace chamber environment. If glass bottles, pressure bags, or any other gas-filled equipment are used inside a hyperbaric chamber, they must be adequately vented and closely monitored during a treatment.

image Adverse Effects

Most HBO2 chamber facilities have equipment and treatment protocols analogous to an ICU. The inherent toxicity of O2 and potential for injury due to elevations of ambient pressure must be addressed whenever HBO2 is used therapeutically.

Barotrauma

Middle ear barotrauma is the most common adverse effect of HBO2 treatment.91 As the ambient pressure within the hyperbaric chamber is increased, a patient must be able to equalize the pressure within the middle ear by auto-insufflation, or else pain followed by hemorrhage, serous effusion, or rupture will develop. Standard protocols include instruction of patients on auto-insufflation techniques and adding oral or topical decongestants when needed. When these interventions fail, tympanostomy tubes must be placed. The incidence of tube placement has been reported to be approximately 4% in one series.92 Others report an overall incidence of aural barotrauma to be between 1.2% and 7%.93,94

Pulmonary barotrauma during HBO2 treatment is extremely rare but should be suspected when any significant chest or hemodynamic symptoms occur during or shortly after decompression. Because the offending gas in virtually all cases will be pure O2, absorption within the body may occur. If symptoms do develop, however, decompression should be stopped and the patient evaluated. If pneumothorax is suspected, placement of a chest tube is appropriate. Preexisting pneumothorax should be treated with chest tube drainage before initiating therapy.

Oxygen Toxicity

Biochemical toxicity due to O2 can be manifested by injuries to lungs, CNS, and eyes. Pulmonary insults can impair mechanics (elasticity), vital capacity, and gas exchange.94 These changes are typically observed only when treatment duration and pressures exceed typical therapeutic protocols. There is one report of reversible small-airway changes in 4 of 21 patients treated daily for 90 minutes at 2.4 ATA for 21 days.95 Most studies have failed to identify any adverse pulmonary effect from standard protocols.96,97,98

CNS O2 toxicity is manifested as a grand mal seizure. This occurs at an incidence of approximately 1 to 4 in 10,000 patient treatments.93,99,100 The risk is higher in hypercapnic patients and possibly those who are acidotic or with compromise due to sepsis, because an incidence of 7% (23 in 322 patients) was reported in case series of HBO2 treatment of gas gangrene.54 Seizures are managed by reducing the inspired O2 tension while leaving the patient at the same ambient pressure (to avoid pulmonary overexpansion injury when a patient is in tonic convulsion phase). Pathologic changes in association with isolated O2-mediated seizures have not been found in studies with guinea pigs, rabbits, and humans.101

Progressive myopia has been reported in patients who undergo prolonged daily therapy, but this typically reverses within 6 weeks after termination of treatments.102 There is a risk for nuclear cataract development, most typically when treatments exceed a total of 150 to 200 hours, but they may arise with less provocative exposures.103,104 Although there is a theoretical risk for retrolental fibroplasia in neonates,105 there are no reports of this having occurred. Currently, experimental and clinical evidence does not indicate that typical HBO2 therapy protocols have detrimental effects on neonates or the unborn fetus.106 This is likely due to the relatively short duration of hyperoxia.

Annotated References

Bouachour G, Cronier P, Gouello JP, et al. Hyperbaric oxygen therapy in the management of crush injuries: a randomized double-blind placebo-controlled clinical trial. J Trauma. 1996;41(2):333-339.

This blinded, randomized trial of 36 crush injury patients documented efficacy of hyperbaric oxygen therapy in improving wound healing and reducing repetitive surgery, particularly in those older than 40 years and with severe (grade III) injuries.

Goldman RJ. Hyperbaric oxygen therapy for wound healing and limb salvage: a systematic review. PM R. 2009;1(5):471-489.

This recent meta-analysis provides a useful overview on the benefits of HBO2 for refractory diabetic wound healing.

Marx RE, Johnson RP, Kline SN. Prevention of osteoradionecrosis: a randomized prospective clinical trial of hyperbaric oxygen versus penicillin. J Am Dent Assoc. 1985;111(1):49-54.

This prospective randomized trial of 74 patients who required dental extractions after receiving in excess of 6800 cGy external beam radiotherapy demonstrated efficacy of prophylactic hyperbaric oxygen therapy in reducing the incidence and severity of postoperative osteoradionecrosis.

Weaver LK, Hopkins RO, Chan KJ, et al. Hyperbaric oxygen for acute carbon monoxide poisoning. N Engl J Med. 2002;347(14):1057-1067.

This prospective, randomized, placebo-controlled trial of 152 patients with carbon monoxide poisoning describes the efficacy of hyperbaric oxygen therapy in reducing neurologic morbidity among those with a history of unconsciousness, or with cerebellar dysfunction, or those with a carboxyhemoglobin level greater than 25%.

References

1 Thom SR. Hyperbaric oxygen therapy. Intensive Care Med. 1989;4:58.

2 Gesell LE. Hyperbaric Oxygen Therapy Indications, 12th ed. Durham, NC: Undersea and Hyperbaric Medical Society; 2008.

3 Thom SR. Oxidative stress is fundamental to hyperbaric oxygen therapy. J Appl Physiol. 2009;106:988.

4 Moon R, Gorman D. Treatment of the decompression disorders. Brubakk A, Neuman T, editors. Physiology and Medicine of Diving. 5th ed. 2003;600.

5 Bray P, Myers RAM, Cowley RA. Orogenital sex as a cause of nonfatal air embolism in pregnancy. Obstet Gynecol. 1983;61:653.

6 Conahan TJ3rd. Air embolization during percutaneous Swan-Ganz catheter placement. Anesthesiology. 1979;50:360.

7 Mader JT, Hulet WH. Delayed hyperbaric treatment of cerebral air embolism. Arch Neurol. 1979;36:504.

8 Majendie F. Sur l’entree accidentelle de l’air dans les veins. J Physiol Exper (Paris). 1821;1:190.

9 Takita H, Olszewski W, Schimert G, et al. Hyperbaric treatment of cerebral air embolism as a result of open-heart surgery. J Thorac Cardiovasc Surg. 1968;55:682.

10 McDermott JJ, Dutka AJ, Koller WA, et al. Effects of an increased PO2 during recompression therapy for the treatment of experimental cerebral arterial gas embolism. Undersea Biomed Res. 1992;19:403.

11 Brown OR. Reversible inhibition of respiration of Escherichia coli by hyperoxia. Microbios. 1972;5:7.

12 Brubakk A, Duplancic D, Valic Z, et al. A single air dive reduces arterial endothelial function. J Physiol. 2005;566(3):901.

13 Lehtosalo J, Tervo T, Laitinen LA. Bubbles and hematologic alterations in intracranial veins during experimental decompression sickness. Acta Neuropathol. 1983;59:139.

14 Levin LL, Stewart GJ, Lynch PR, et al. Blood and blood vessel wall changes induced by decompression sickness in dogs. J Appl Physiol. 1981;50:944.

15 Nossum V, Koteng S, Brubakk A. Endothelial damage by bubbles in the pulmonary artery of the pig. Undersea Hyperb Med. 1999;26:1.

16 Martin JD, Thom SR. Vascular leukocyte sequestration in decompression sickness and prophylactic hyperbaric oxygen therapy in rats. Aviat Space Environ Med. 2002;73:565.

17 Nossum V, Hjelde A, Brubakk A. Small amounts of venous gas embolism cause delayed impairment of endothelial function and increase polymorphonuclear neutrophil infiltration. Eur J Appl Physiol. 2002;86:209.

18 Helps SC, Gorman DF. Air embolism of the brain in rabbits pretreated with mechlorethamine. Stroke. 1991;22:351.

19 Thom SR, Mendiguren I, Hardy K, et al. Inhibition of human neutrophil beta2-integrin-dependent adherence by hyperbaric O2. Am J Physiol. 1997;272:C770.

20 Atochin D, Fisher D, Demchenko I, et al. Neutrophil sequestration and the effect of hyperbaric oxygen in a rat model of temporary middle cerebral artery occlusion. Undersea Hyperb Med. 2000;27:185.

21 Thom S, Mendiguren I, Fisher D. Smoke inhalation-induced alveolar lung injury is inhibited by hyperbaric oxygen. Undersea Hyperb Med. 2002;28:175.

22 Thom SR. Functional inhibition of leukocyte B2 integrins by hyperbaric oxygen in carbon monoxide-mediated brain injury in rats. Toxicol Appl Pharmacol. 1993;123:248.

23 Zamboni WA, Roth AC, Russell RC, et al. Morphologic analysis of the microcirculation during reperfusion of ischemic skeletal muscle and the effect of hyperbaric oxygen. Plast Reconstr Surg. 1993:91.

24 Thom S, Bhopale V, Mancini J, et al. Actin S-nitrosylation inhibits neutrophil beta-2 integrin function. J Biol Chem. 2008;283:10822.

25 Raub JA, Mathieu-Nolf M, Hampson NB, et al. Carbon monoxide poisoning–a public health perspective. Toxicology. 2000;145:1.

26 Choi S. Delayed neurologic sequelae in carbon monoxide intoxication. Arch Neurol. 1983;40:433.

27 Gorman DF, Clayton D, Gilligan JE, et al. A longitudinal study of 100 consecutive admissions for carbon monoxide poisoning to the Royal Adelaide Hospital. Anaesth Intensive Care. 1992;20:311.

28 Mathieu D, Wattel F, Mathieu-Nolf M, et al. Randomized prospective study comparing the effect of HBO versus 12 hours NBO in non-comatose CO poisoned patients. Undersea Hyperb Med. 1996;23(suppl.):7.

29 Myers RAM, Snyder SK, Emhoff TA. Subacute sequelae of carbon monoxide poisoning. Ann Emerg Med. 1985;14:1163.

30 Raphael JC, Elkharrat D, Guincestre MCJ, et al. Trial of normobaric and hyperbaric oxygen for acute carbon monoxide intoxication. Lancet. 1989:414.

31 Thom SR, Taber RL, Mendiguren II, et al. Delayed neuropsychologic sequelae after carbon monoxide poisoning: prevention by treatment with hyperbaric oxygen. Ann Emerg Med. 1995;25:474.

32 Weaver LK, Hopkins RO, Chan KJ, et al. Hyperbaric oxygen for acute carbon monoxide poisoning. N Engl J Med. 2002;347:1057.

33 Andre L, Boissiere J, Reboul C, et al. Carbon monoxide pollution promotes cardiac remodeling and ventricular arrhythmia in healthy rats. Am J Respir Crit Care Med. 2009;181:587.

34 Ishimaru H, Katoh A, Suzuki H, et al. Effects of N-methyl-D-aspartate receptor antagonists on carbon monoxide-induced brain damage in mice. J Pharmacol Exp Ther. 1992;261:349.

35 Maurice T, Hiramatsu M, Kameyama T, et al. Cholecystokinin-related peptides, after systemic or central administration, prevent carbon monoxide-induced amnesia in mice. J Pharmacol Exp Ther. 1994;269:665.

36 Nabeshima T, Katoh A, Ishimaru H, et al. Carbon monoxide-induced delayed amnesia, delayed neuronal death and change in acetylcholine concentration in mice. J Pharm Exp Ther. 1991;256:378.

37 Piantadosi CA, Tatro L, Zhang J. Hydroxyl radical production in the brain after CO hypoxia in rats. Free Rad Biol Med. 1995;18:603.

38 Thom S, Bhopale V, Han S-T, et al. Intravascular neutrophil activation due to carbon monoxide poisoning. Am J Respir Crit Care Med. 2006;174:1239.

39 Thom SR. Carbon monoxide-mediated brain lipid peroxidation in the rat. J Appl Physiol. 1990;68:997.

40 Brown SD, Piantadosi CA. Recovery of energy metabolism in rat brain after carbon monoxide hypoxia. J Clin Invest. 1991;89:666.

41 Thom SR. Antagonism of carbon monoxide-mediated brain lipid peroxidation by hyperbaric oxygen. Toxicol Appl Pharmacol. 1990;105:340.

42 End E, Long CW. Oxygen under pressure in carbon monoxide poisoning. J Ind Hyg Toxicol. 1942;24:302.

43 Pearce EC, Zacharias A, Alday J, et al. Carbon monoxide poisoning: experimental hypothermic and hyperbaric studies. Surgery. 1972;72:229.

44 Thom SR. Learning dysfunction and metabolic defects in globus pallidus and hippocampus after CO poisoning in a rat model. Undersea Hyperb Med. 1997;23:20.

45 Juurlink DN, Buckley NA, Stanbrook MB, et al. Hyperbaric oxygen for carbon monoxide poisoning Cochrane Database Syst Rev 2005;Jan 25; (1): CD002041

46 Ducasse JL, Celsis P, Marc-Vergnes JP. Non-comatose patients with acute carbon monoxide poisoning: hyperbaric or normobaric oxygenation? Undersea Hyperb Med. 1995;22:9.

47 Scheinkestel C, Bailey M, Myles P, et al. Hyperbaric or normobaric oxygen for acute carbon monoxide poisoning: a randomised controlled clinical trial. Med J Aust. 1999;170:203.

48 Hampson NB, Mathieu D, Piantadosi CA, et al. Carbon monoxide poisoning: Interpretation of randomized clinical trials and unresolved treatment issues. Undersea Hyperb Med. 2001;28:157.

49 Weaver LK, Hopkins RO, Chan KJ, et al. Carbon monoxide research group: LDS Hospital, Utah in reply to Sheinkestel, et al. and Emerson: the role of hyperbaric oxygen in carbon monoxide poisoning. Emerg Med Australas. 2004;16:394.

50 Amonic RS, Cockett ATK, Lorhan P, et al. Hyperbaric oxygen in chronic hemorrhagic shock. JAMA. 1969;208(11):2051-2054.

51 Hart GB. Exceptional blood loss anemia. Treatment with hyperbaric oxygen. JAMA. 1974;228:1028.

52 McLoughlin P, Cope T, Harrison J. Hyperbaric oxygen therapy in the management of severe acute anaemia in a Jehovah’s witness. Anaesthesia. 1999;54:879.

53 Myking O, Schreiner A. Hyperbaric oxygen in hemolytic crisis. JAMA. 1974;227:1161.

54 Hart GB, Lamb RC, Strauss MB. Gas gangrene: I. A collective review. J Trauma. 1983;23:991.

55 Hirn M, Niinikoski J. Hyperbaric oxygen in the treatment of clostridial gas gangrene. Ann Chir Gynaecol. 1988;77:37.

56 Bouachour G, Cronier P, Gouello JP, et al. Hyperbaric oxygen therapy in the management of crush injuries: a randomized double-blind placebo-controlled clinical trial. J Trauma. 1996;41:333.

57 Mathieu D, Wattel F, Bouachour G, et al. Post-traumatic limb ischemia: prediction of final outcome by transcutaneous oxygen measurements in hyperbaric oxygen. J Trauma. 1990;30:307.

58 Bergofsky EH, Bertun P. Response of regional circulations to hyperoxia. J Appl Physiol. 1966;21:567.

59 Bird AD, Telfer AB. Effect of Hyperbaric Oxygen on Limb Circulation. Lancet. 1965;1:355.

60 Strauss MB, Hargens AR, Gershuni DH, et al. Reduction of skeletal muscle necrosis using intermittent hyperbaric oxygen in a model compartment syndrome. J Bone Joint Surg. 1983;65:656.

61 Roje Z, Roje Z, Eterovic D, et al. Influence of adjuvant hyperbaric oxygen therapy on short-term complications during surgical reconstruction of upper and lower extremity war injuries: retrospective cohort study. Croat Med J. 2008;49:224.

62 Barzilai A, Zaaroor M, Toledano C. Necrotizing fasciitis: early awareness and principles of treatment. Isr J Med Sci. 1985;21:127.

63 Brown DR, Davis NL, Lepawsky M, et al. A multicenter review of the treatment of major truncal necrotizing infections with and without hyperbaric oxygen therapy. Am J Surg. 1994;167:485.

64 Eltorai IM, Hart GB, Strauss MB, et al. The role of hyperbaric oxygen in the management of Fournier’s gangrene. Int Surg. 1986;71:53.

65 Gozal D, Ziser A, Shupak A, et al. Necrotizing fasciitis. Arch Surg. 1986;121:233.

66 Hollabaugh RSJr, Dmochowski RR, Hickerson WL, et al. Fournier’s gangrene: therapeutic impact of hyperbaric oxygen. Plast Reconstr Surg. 1998;101:94.

67 Korhonen K. Hyperbaric oxygen therapy in acute necrotizing infections with a special reference to the effects on tissue gas tensions. Ann Chir Gynaecol Suppl. 2000;214:7-36.

68 Korhonen K, Hirn M, Niinikoski J. Hyperbaric oxygen in the treatment of Fournier’s gangrene. Eur J Surg. 1998;164:251.

69 Riseman JA, Zamboni WA, Curtis A, et al. Hyperbaric oxygen therapy for necrotizing fasciitis reduces mortality and the need for debridements. Surgery. 1990;108:847.

70 Sawin RS, Schaller RT, Tapper D, et al. Early recognition of neonatal abdominal wall necrotizing fasciitis. Am J Surg. 1994;167:481.

71 Shupak A, Shoshani O, Goldenberg I, et al. Necrotizing fasciitis: an indication for hyperbaric oxygenation therapy? Surgery. 1995;118:873.

72 Zamboni WA, Mazolewski PJ, Erdmann D, et al. Evaluation of penicillin and hyperbaric oxygen in the treatment of streptococcal myositis. Ann Plast Surg. 1997;39:131.

73 Ollodart R, Blair E. High-pressure oxygen as an adjunct in experimental bacteremic shock. JAMA. 1965;191:132.

74 Ross RM, McAllister TA. Protective action of hyperbaric oxygen in mice with pneumococcal septicaemia. Lancet. 1965:579.

75 Thom SR, Lauermann MW, Hart GB. Intermittent hyperbaric oxygen therapy for reduction of mortality in experimental polymicrobial sepsis. J Infect Dis. 1986;154:504.

76 Hill GB, Osterhout S. Experimental effects of hyperbaric oxygen on selected clostridical species. I. In-vitro studies. J Infect Dis. 1972;125:17.

77 Mader JT, Brown GL, Guckian JC, et al. A mechanism for the amelioration by hyperbaric oxygen of experimental staphylococcal osteomyelitis in rabbits. J Infect Dis. 1980;142:915.

78 Park MK, Muhvich KH, Myers RAM, et al. Hyperoxia prolongs the aminoglycoside-induced post antibiotic effect in pseudomonas aeruginosa. Antimicrob Agents Chemother. 1991;35:691.

79 Brannen AL, Still J, Haynes MS, et al. A randomized prospective trial of hyperbaric oxygen in a referral burn center population. Am Surg. 1997;63:205-208.

80 Cianci P, Lueders H, Lee H, et al. Adjunctive hyperbaric oxygen reduces the need for surgery in 40-80% burns. J Hyperb Med. 1988;3:97.

81 Hart GB, O’Reilly RR, Broussard ND, et al. Treatment of burns with hyperbaric oxygen. Surg Gynecol Obstet. 1974;139:693.

82 Niu AKC, Yand C, Lee HC, et al. Burns treated with adjunctive hyperbaric oxygen therapy: a comparative study in humans. 1987;2.

83 Grossman RA. Hyperbaric oxygen in the treatment of burns. Ann Plastic Surg. 1978;1:163.

84 Waisbren BA, Schutz D, Collentine G, et al. Hyperbaric oxygen in severe burns. Burns. 1982;8:176.

85 Wiseman DH, Grossman AR. Hyperbaric oxygen in the treatment of burns. Crit Care Clin. 1985;1:129.

86 Goldman RJ. Hyperbaric oxygen therapy for wound healing and limb salvage: a systematic review. PM R. 2009;1(5):471489.

87 Kranke P, Bennett M, Roeckl-Wiedmann I, et al. Hyperbaric oxygen therapy for chronic wounds. Cochrane Database Syst Rev 2004;CD004123.

88 Bennett M, Feldmeier J, Hampson N, et al. Hyperbaric oxygen therapy for late radiation tissue injury (Cochrane review). The Cochrane Library. 2008. Issue 1

89 Clarke R, Tenorio C, Hussey J, et al. Hyperbaric oxygen treatment of chronic radiation proctitis: A randomized and controlled double blind crossover trial with long-term follow-up. Int J Radiat Oncol Biol Phys. 2008;72:134-143.

90 Marx RE, Johnson RP, Kline SN. Prevention of osteoradionecrosis: a randomized prospective clinical trial of hyperbaric oxygen versus penicillin. J Am Dent Assoc. 1985;111:49.

91 Carlson S, Jones J, Brown M. Prevention of hyperbaric-associated middle ear barotrauma. Ann Emerg Med. 1992;21:1468.

92 Clements KS, Vrabec JT, Mader JT. Complications of tympanostomy tubes inserted for facilitation of hyperbaric oxygen therapy. Arch Otolaryngol Head Neck Surg. 1998;124:278.

93 Plafki C, Peters P, Almeling M, et al. Complications and side effects of hyperbaric oxygen therapy. Aviat Space Environ Med. 2000;71:119.

94 Trytko B, Bennett M. Hyperbaric oxygen therapy: complication rates are much lower than authors suggest. Br Med J. 1999;318:1077.

95 Thorsen E, Aanderud L, Aasen TB. Effects of a standard hyperbaric oxygen treatment protocol on pulmonary function. Eur Respir J. 1998;12:1442.

96 Clark JM, Lambersten CJ. Rate of development of pulmonary O2 toxicity in man during O2 breathing at 2.0 atm absolute. J Appl Physiol. 1971;30:739.

97 Hart GB, Strauss MB, Riker J. Vital capacity of quadriplegic patients treated with hyperbaric oxygen. J Am Paraplegia Soc. 1984;7:113.

98 Rusca F, Garetto G, Ambrosio F. HBO Therapy and pulmonary function tests. Undersea Biomed Res. 1991;18:112.

99 Davis JC, Dunn JM, Heimbach RD. Hyperbaric medicine: patient selection, treatment procedures, and side-effects. In: Davis JC, Hunt TK, editors. Problem Wounds. New York: Elsevier; 1988:225.

100 Hart GB, Strauss MB. Central nervous system oxygen toxicity in a clinical setting. In: Bove AA, Bachrack AJ, Greenbaum LJ, editors. Undersea and Hyperbaric Physiology IX. Bethesda: Undersea and Hyperbaric Medical Society; 1987:695.

101 Clark JM. Oxygen toxicity. In: Bennett PB, Elliott DH, editors. The Physiology and Medicine of Diving and Compressed Air Work. London: Balliere; 1983:200.

102 Lyne AJ. Ocular effects of hyperbaric oxygen. Trans Ophthalmol Soc U K. 1978;98:66.

103 Gesell L, Trott A. De novo cataract development following a standard course of hyperbaric oxygen therapy. Undersea Hyperb Med. 2007;34:389.

104 Palmquist BM, Philipson BO, Barr PO. Nuclear cataract and myopia during hyperbaric oxygen therapy. Br J Ophthalmol. 1984;68:113.

105 Patz A. The effect of oxygen on immature retinal vessels. Invest Ophthalmol. 1965;4:988.

106 Van Hoesen K, Camporesi EM, Moon RE, et al. Should hyperbaric oxygen be used to treat the pregnant patient for acute carbon monoxide poisoning? A case report and literature review. JAMA. 1989;261:1039.

107 Sheffield PJ, Desautels DA. Hyperbaric and hypobaric chamber fires: a 73-year analysis. Undersea Hyperb Med. 1997;24:153.